<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>&#43;Vaccination on Vishvas&#39;s notes</title>
    <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/</link>
    <description>Recent content in &#43;Vaccination on Vishvas&#39;s notes</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <atom:link href="https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Approaches</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Approaches/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Approaches/</guid>
      <description>&lt;h2 id=&#34;mrna-for-spike-protein&#34;&gt;mRNA for spike protein&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;COVID-19 mRNA vaccines give instructions for our cells to make “spike protein”, which gets desposited on cell surface. Then, an immune response to them devolops.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;spike-protein-injection&#34;&gt;Spike protein injection&lt;/h2&gt;&#xA;&lt;p&gt;Trigger antibody development thence.&lt;/p&gt;&#xA;&lt;h2 id=&#34;foiling-spike-protein&#34;&gt;Foiling Spike protein&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Idea is to bind and block S proteins.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 id=&#34;ace2-decoys&#34;&gt;ACE2 decoys&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Entry of the virus which happens through binding of Spike (S) protein of the virus with ACE2 receptors found in the lungs. If you use decoy ACE2 substance (which bind better),the virus might bind to this synthetic ACE2 rather than original ACE2 receptors resulting in less viruses thus reducing the inflammation in the lungs. The main problem is the short half life of this synthetic ACE2. Scientists are working how to increase the half life.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;viral-vector-vaccines&#34;&gt;Viral vector vaccines&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;viral vector vaccines blood clots are happening - J&amp;amp;J, Oxford.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;inactivated-viral-vaccines&#34;&gt;Inactivated viral vaccines&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Hepatitis A and Salk Polio virus are inactivated vaccines. These vaccines have adjuvants with alum or aluminium that can cause severe reactions at injection site as opposed to mRNA or DNA vaccines.&lt;/li&gt;&#xA;&lt;li&gt;Dr Kang expresses reservations if the inactivated vaccines like COVAXIN work with new mutants as the mutations are occurring at the spike of the virus.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Failed attempts</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Failed_attempts/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Failed_attempts/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;BCG vaccination effect.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Herd immunity levels</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/herd-immunity/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/herd-immunity/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;With the original Wuhan virus,experts felt once 67% of the population are protected cases will come down.&lt;/li&gt;&#xA;&lt;li&gt;Next came Alpha variant( B 117) this number got increased to  75%&lt;/li&gt;&#xA;&lt;li&gt;Then came Delta variant( B 1.617.2) this further increased to  83%.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>India</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/India/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/India/</guid>
      <description>&lt;h2 id=&#34;approvals&#34;&gt;Approvals&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;J&amp;amp;J vaccine will &amp;lsquo;get back on track soon&amp;rsquo;&lt;/li&gt;&#xA;&lt;li&gt;Sputnik V 202104&lt;/li&gt;&#xA;&lt;li&gt;Bharat Biotech - approved &amp;ldquo;in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains&amp;rdquo;.&lt;/li&gt;&#xA;&lt;li&gt;Oxford/ AstraZeneca. manufactured locally by the Serum Institute of India.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;immunization-priority&#34;&gt;Immunization priority&lt;/h2&gt;&#xA;&lt;p&gt;60% of vaccines globally, plans to immunise about 300 million people by July 2021. It will prioritise health care workers, the emergency services, and those who are clinically vulnerable because of age or pre-existing conditions.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Natural infection</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Natural_infection/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Natural_infection/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;See &lt;a href=&#34;../reinfection&#34;&gt;reinfection&lt;/a&gt; page.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Other Trials as of 2020-12</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Other_Trials_as_of_2020-12/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Other_Trials_as_of_2020-12/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;FDA standards - &amp;ldquo;If a particular vaccine doesn&amp;rsquo;t demonstrate a minimum of 50 percent efficacy, it will not be approved.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Side effect mitigation</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/side-effect-mitigation/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/side-effect-mitigation/</guid>
      <description>&lt;h2 id=&#34;thrombosis-with-thrombocytopenia-syndrome-tts&#34;&gt;Thrombosis with Thrombocytopenia Syndrome (TTS)&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Reference sheet &lt;a href=&#34;https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia&#34;&gt;here&lt;/a&gt;.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Vipin&#39;s summary</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Vipins_summary/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/Vipins_summary/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;1-Ten different Covid-19 vaccines have shared their Phase III data; 2 based on mRNA, 4 on viral vector, 3 on inactivated &amp;amp; 1 on protein subunit platform&lt;/li&gt;&#xA;&lt;li&gt;2-After 4 months of their trials, now there is a definite gradient in their performance:&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Highly efficacious: mRNA, moderate: viral vector, &amp;amp; low to moderate: inactivated vaccines.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;3- Efficacy (Point estimates as per published/shared data): Pfizer 95%; Moderna 94.1%, Sputnik-V 91.6%, Novavax 89.3%, AstraZeneca (AZ) 62-90%, Sinopharm’s (BBIBP-CorV) 79%, Covaxin 78%, JNJ 72%, CanSino’s 65.7%, &amp;amp; Sinovac’s (CoronaVac) 50.4%.&lt;/li&gt;&#xA;&lt;li&gt;4-Quality of evidence (confidence):&#xA;&lt;ul&gt;&#xA;&lt;li&gt;• Highest (Real world use, Effectiveness data &amp;amp; Publication of Efficacy trial)-Pfizer, AstraZeneca &amp;amp; Moderna;&lt;/li&gt;&#xA;&lt;li&gt;• Moderate (Real world use, Publication of efficacy trial): JNJ, Sputnik-V, Sinopharm, &amp;amp; Novavax;&lt;/li&gt;&#xA;&lt;li&gt;• Low-moderate (Real world data, no publication of efficacy trial): CanSino, Sinovac &amp;amp; Covaxin&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;5-Israel, Chile, Bahrein, US &amp;amp; UK are the 5 leading countries as far as highest share of fully vaccinated population is concerned&lt;/li&gt;&#xA;&lt;li&gt;10- Breakthrough infections observed with almost all vaccines. Most mild &amp;amp; moderate, deaths are also seen in fully vaccinated (out of 5800 breakthrough cases with mRNA vaccines in the US, 7% hospitalized &amp;amp; 74 died)&lt;/li&gt;&#xA;&lt;li&gt;11-Most vaccines have comparatively lower efficacy in elderly &amp;amp; comorbidities than in younger and healthy people&lt;/li&gt;&#xA;&lt;li&gt;12-Most gene-based vaccines (mRNA &amp;amp; Viral vector) have high reactogenicity profile.&lt;/li&gt;&#xA;&lt;li&gt;13-Adenovirus vector-based vaccines (AZ &amp;amp; JNJ) have rare, serious adverse events called VITT (vaccine induced immune thrombotic thrombocytopenia). Incidence varies from 1 case in 40 000 to 1 in 100 000, but the benefits far outweigh than the risks&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;ol start=&#34;14&#34;&gt;&#xA;&lt;li&gt;Efficacy against variants: Most vaccines have only very modest reductions in efficacy against UK’s B117 &amp;amp; Brazil’s P1 variants. Most vaccines have lower efficacy against South Africa’s B1351 variant (containing E484K mutation).&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;15-AZ vaccine has got only 10% efficacy against B1351 variant, whereas JNJ (57%) &amp;amp; Novavax (49%) had major reductions in efficacy trials. Sputnik-V, Pfizer &amp;amp; Moderna vaccines have reduced neutralization against B1351.&lt;/li&gt;&#xA;&lt;li&gt;16-Pfizer vaccine has shown intact efficacy against B1351 in Qatar in real world evidence after 2 doses. Nevertheless, most leading vaccines are developing boosters with revised formulation to tackle B1351 variant.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;17-So far, natural infection induced protection seems to be more lasting than vaccine induced, particularly in context with non-mRNA vaccines.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;18-Only 4 vaccine candidates elicited several folds higher titers of neutralizing antibodies (NAbs) than natural infection (NAbs titers measured in human convalescent serum): Pfizer, Moderna, Novavax &amp;amp; Sputnik-V.  However, natural immunity is much more broader.&lt;/li&gt;&#xA;&lt;li&gt;19- We know now that natural infection provides at least 8 months of protection. Whereas mRNA vaccines are found to provide protection at least for 6 months without any appreciable loss of efficacy. Other vaccines like inactivated &amp;amp; AZ vaccines may provide lesser duration of protection.&lt;/li&gt;&#xA;&lt;li&gt;20-Natural infection may provide resistance against immune evader variants also since there is immune responses against not only against S protein but against other antigens of the virus. Further, the variants do not have changes in T-cell epitopes.&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;ol start=&#34;22&#34;&gt;&#xA;&lt;li&gt;Those had natural infection can wait for THREE MONTHS for their Covid vaccine shot.&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;ol start=&#34;23&#34;&gt;&#xA;&lt;li&gt;In previously infected individuals with anti-spike IgG positive individuals, only ONE DOSE of mRNA vaccine is sufficient!&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;ol start=&#34;21&#34;&gt;&#xA;&lt;li&gt;Most vaccines elicit both humoral and T cell immunity. However, viral vector vaccine, particularly AZ vaccine has got particularly good CD8 cell response which kill virus infected cell and ameliorate severity of disease.&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;ol start=&#34;28&#34;&gt;&#xA;&lt;li&gt;Several vaccines are now conducting trials for use of Covid vaccines in pediatric population. Pfizer showed 100% efficacy in 12-15 yrs old, Moderna is doing trial in 6mo to 12 yrs (in US) &amp;amp; 5-11 yrs (in Canada), JNJ 12-17 yrs, Sinovac 3-11 yrs &amp;amp; Novavax 12-17 yrs. AZ has paused their trial in 6-17 yrs.&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;vaccine-booster-efficacy-against-omircon&#34;&gt;Vaccine booster efficacy against Omircon&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&#xA;&lt;p&gt;From UKHSA data.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
